
27/05/2025
SLEIPNIR is a first-of-its-kind, multi-arm platform trial specifically designed to assess whether potential disease modifying therapies for Parkinson’s disease engage their intended targets in the patient brain. It aims to reduce early development risks and improve success in later trials. We look forward to launching the first cycle with 120 participants later this year and are deeply grateful to Cure Parkinson's for their vital support of the SLEIPNIR Platform, and to the Norwegian Parkinson’s Research Fund and Norges Parkinsonforbund for their continued support! Read more in the article published by Haukeland universitetssjukehus.
Parkinsons sjukdom er ein kronisk og invalidiserande hjernesjukdom som rammar meir enn 10 millionar mennesker globalt. Det finst inga behandling som kan bremse sjukdomsutviklinga, trass i meir enn 70 fullførte kliniske behandlingsstudiar på verdsbasis. Ein viktig grunn til dette er manglande kunns...